Government ❯ Politics ❯ Health Policy

Abortion

Mifepristone Medication Abortion Nomination Process Planned Parenthood Pro-Life Movement FDA Regulations Conscientious Objection Mifepristone Approval Vaccine Mandates EMTALA Emergency Medical Treatment Research Studies Drug Approval Legislation Medication Safety Conscience Objection Gender Identity Fetal Tissue Research Telehealth Title X Grants Financial Incentives Mifepristone Safety FDA Leadership Robert F. Kennedy Jr. Pro-Choice Stance Controversial Figures Abortion Rights Confirmation Hearings Mifepristone Regulation Pro-Life Advocacy

HHS Funds Title X for 2026 as It Sets 2027 Shift Toward Natural Family Planning and Abortion Limits

The guidance signals a 2027 redesign prioritizing fertility awareness under stricter abortion restrictions.

HHS Issues New Title X Guidance as Hawley Presses Kennedy on Planned Parenthood Funds

Trump Administration Issues Final Year of Biden-Era Title X Grants, Citing Legal Barriers

HHS Bars Fetal Tissue From Elective Abortions in Federally Funded Research

Live Action Urges HHS and FDA to Suspend Mifepristone After Undercover Planned Parenthood Calls

Republicans Press Trump Administration to Halt Mail-Order Abortion Pills Crossing State Lines

Republicans Push to Restore In‑Person Rules for Abortion Pill at Fiery Senate Hearing

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

Senate Democrats Press FDA on Mifepristone Review After Court Strikes Down Restrictions

GOP Senators Press FDA Over Generic Abortion Pill Approval